File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Review article: Current management of metastatic colorectal cancer - The evolving impact of targeted drug therapies

TitleReview article: Current management of metastatic colorectal cancer - The evolving impact of targeted drug therapies
Authors
Issue Date2008
PublisherBlackwell Publishing Ltd. The Journal's web site is located at http://www.blackwellpublishing.com/journals/APT
Citation
Alimentary Pharmacology And Therapeutics, 2008, v. 27 n. 11, p. 997-1005 How to Cite?
AbstractBackground: The field of colorectal cancer chemotherapy has been transformed by the advent of molecule-specific drugs. Combined use of such drugs enhances tumour response rates, but controlled data quantifying the relative efficacy and cost-effectiveness of different drug combinations on overall survival remain scarce. Aim: To conduct an overview of published clinical trials in advanced colorectal cancer, with the objective of framing provisional approaches to current management. Methods: An NCBI/PubMed search was performed using the strings, 'colorectal cancer' ('metastatic' or 'advanced' or 'palliative') and ('chemotherapy' or 'drug therapy' or 'targeted' or 'target-specific' or 'molecularly-targeted'). Results: Combinations of target-specific drugs (with or without the DNA-alkylating agent oxaliplatin) have substantially enhanced colorectal cancer time to progression over the last decade and have also expedited surgical resection of liver metastases. Disease-free survival, overall survival and quality of life are favourably influenced. Conclusions: Target-specific drugs improve palliative efficacy in the setting of advanced colorectal cancer. However, key issues persist as to the cost-effectiveness of these newer drug treatments, and further controlled trials are needed to resolve this important debate. © 2008 The Authors.
Persistent Identifierhttp://hdl.handle.net/10722/132657
ISSN
2015 Impact Factor: 6.32
2015 SCImago Journal Rankings: 2.833
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorYau, Ten_HK
dc.contributor.authorChan, Pen_HK
dc.contributor.authorChing Chan, Yen_HK
dc.contributor.authorWong, BCYen_HK
dc.contributor.authorLiang, Ren_HK
dc.contributor.authorEpstein, RJen_HK
dc.date.accessioned2011-03-28T09:27:27Z-
dc.date.available2011-03-28T09:27:27Z-
dc.date.issued2008en_HK
dc.identifier.citationAlimentary Pharmacology And Therapeutics, 2008, v. 27 n. 11, p. 997-1005en_HK
dc.identifier.issn0269-2813en_HK
dc.identifier.urihttp://hdl.handle.net/10722/132657-
dc.description.abstractBackground: The field of colorectal cancer chemotherapy has been transformed by the advent of molecule-specific drugs. Combined use of such drugs enhances tumour response rates, but controlled data quantifying the relative efficacy and cost-effectiveness of different drug combinations on overall survival remain scarce. Aim: To conduct an overview of published clinical trials in advanced colorectal cancer, with the objective of framing provisional approaches to current management. Methods: An NCBI/PubMed search was performed using the strings, 'colorectal cancer' ('metastatic' or 'advanced' or 'palliative') and ('chemotherapy' or 'drug therapy' or 'targeted' or 'target-specific' or 'molecularly-targeted'). Results: Combinations of target-specific drugs (with or without the DNA-alkylating agent oxaliplatin) have substantially enhanced colorectal cancer time to progression over the last decade and have also expedited surgical resection of liver metastases. Disease-free survival, overall survival and quality of life are favourably influenced. Conclusions: Target-specific drugs improve palliative efficacy in the setting of advanced colorectal cancer. However, key issues persist as to the cost-effectiveness of these newer drug treatments, and further controlled trials are needed to resolve this important debate. © 2008 The Authors.en_HK
dc.languageengen_US
dc.publisherBlackwell Publishing Ltd. The Journal's web site is located at http://www.blackwellpublishing.com/journals/APTen_HK
dc.relation.ispartofAlimentary Pharmacology and Therapeuticsen_HK
dc.rightsAlimentary Pharmacology and Therapeutics. Copyright © Blackwell Publishing Ltd.-
dc.subject.meshAntineoplastic Agents - economics - therapeutic useen_HK
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols - economics - therapeutic useen_HK
dc.subject.meshChemotherapy, Adjuvanten_HK
dc.subject.meshClinical Trials as Topicen_HK
dc.subject.meshColorectal Neoplasms - drug therapyen_HK
dc.subject.meshCost-Benefit Analysisen_HK
dc.subject.meshDrug Delivery Systemsen_HK
dc.subject.meshHumansen_HK
dc.titleReview article: Current management of metastatic colorectal cancer - The evolving impact of targeted drug therapiesen_HK
dc.typeArticleen_HK
dc.identifier.emailYau, T:tyaucc@hku.hken_HK
dc.identifier.emailWong, BCY:bcywong@hku.hken_HK
dc.identifier.emailLiang, R:rliang@hku.hken_HK
dc.identifier.emailEpstein, RJ:repstein@hku.hken_HK
dc.identifier.authorityYau, T=rp01466en_HK
dc.identifier.authorityWong, BCY=rp00429en_HK
dc.identifier.authorityLiang, R=rp00345en_HK
dc.identifier.authorityEpstein, RJ=rp00501en_HK
dc.description.naturelink_to_OA_fulltexten_US
dc.identifier.doi10.1111/j.1365-2036.2008.03684.xen_HK
dc.identifier.pmid18363897-
dc.identifier.scopuseid_2-s2.0-42949164905en_HK
dc.identifier.hkuros150566-
dc.identifier.hkuros150592-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-42949164905&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume27en_HK
dc.identifier.issue11en_HK
dc.identifier.spage997en_HK
dc.identifier.epage1005en_HK
dc.identifier.eissn1365-2036-
dc.identifier.isiWOS:000255463200001-
dc.publisher.placeUnited Kingdomen_HK
dc.identifier.scopusauthoridYau, T=23391533100en_HK
dc.identifier.scopusauthoridChan, P=7403497715en_HK
dc.identifier.scopusauthoridChing Chan, Y=24168080100en_HK
dc.identifier.scopusauthoridWong, BCY=7402023340en_HK
dc.identifier.scopusauthoridLiang, R=26643224900en_HK
dc.identifier.scopusauthoridEpstein, RJ=34975074500en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats